Millennium Pharmaceuticals Limited

Takeda Pharmaceutical Company Limited

Brian Scott Freeze

Koji Ono

Steven P Langston

Zhan Shi

He Xu

Stepan Vyskocil

Hirotake Mizutani

Matthew O Duffey

Dylan Bradley England

Zhigen Hu

Charles McIntyre

Masato Yoshikawa

Masaki Seto

Tsuneo Oda

Todd B Sells

Masaaki Hirose

Yusuke Sasaki

Akito Shibuya

Zenyu Shiokawa

Michiyo Mochizuki

Paul D Greenspan

Morihisa Saitoh

Yusuke Tominari

Hong Myung Lee

Tianlin Xu

Tomohiro Seki

Yasufumi Wada

Taisuke Tawaraishi

Yoshihisa Nakada

Kosuke Hidaka

Yasuo Nakagawa

Yayoi Nakayama

Shumpei Murata

Taisuke Kato

Atsutoshi Okabe

Francois Soucy

Yongbo Hu

Kenneth M Gigstad

Masanori Okaniwa

Leo R Takaoka

David A Janowick

The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

Methods of making a cyclic dinucleotide

Antibody-drug conjugates comprising a cyclic dinucleotide

Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, R, R', R, R, X, X, X, R, Z, and Zhave the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

Heteroaryl compounds useful as inhibitors of SUMO activating enzyme

Heteroaryl compounds useful as inhibitors of sumo activating enzyme

This invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein T, J, R, R, R, o, R, W and Rand subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, and/or T-cell mediated autoimmune disease. 

Quinazoline and quinoline compounds and uses thereof

Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, R, R, R, R, X, X, X, R, Z, and Zhave the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.

This invention provides compounds of formula IA-i-a or IB-i-a and subsets thereof: wherein Z, HY, R, R, R, G, W, n, and A and subsets thereof are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Heteroaryls and uses thereof

This invention provides compounds of formula I-A or I-B: wherein HY, G, G, R, R, W, W, n, and Ring A are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Growing community of inventors

Boston, MA, United States of America

Brian Scott Freeze